Day One Biopharma rises on mid-stage trial data from brain tumor treatment
05/06/2023 11:34
** Shares of therapy developer Day One Biopharmaceuticals
Inc DAWN.O rise ~35% premarket to $18.35
** Co posts positive data from registrational mid-stage
trial for its investigational monotherapy tovorafenib for a type
of brain tumor
** Data shows overall response rate of 67% and clinical
benefit rate of 93% in 69 patients
** The trial evaluated tovorafenib as a once-weekly
monotherapy in patients with types of pediatric low-grade
glioma, which are slow-growing brain tumors
** Co expects to complete rolling marketing application
submission in Oct. 2023 for tovorafenib
** As of last close, stock down ~36% YTD
(Reporting by Sriparna Roy and Pratik Jain in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))